CeriBell (CBLL) Expected to Announce Earnings on Thursday

CeriBell (NASDAQ:CBLL - Get Free Report) is expected to release its Q1 2025 earnings data after the market closes on Thursday, May 8th. Analysts expect CeriBell to post earnings of ($0.43) per share and revenue of $19.30 million for the quarter. CeriBell has set its FY 2025 guidance at EPS.

CeriBell (NASDAQ:CBLL - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). The firm had revenue of $18.53 million during the quarter, compared to analysts' expectations of $17.55 million. On average, analysts expect CeriBell to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

CeriBell Price Performance

NASDAQ:CBLL traded up $0.04 during trading hours on Friday, reaching $16.32. The stock had a trading volume of 208,040 shares, compared to its average volume of 270,817. The stock has a 50 day moving average of $18.85. CeriBell has a 12-month low of $10.01 and a 12-month high of $32.75.

Analyst Upgrades and Downgrades

Several analysts have issued reports on CBLL shares. LADENBURG THALM/SH SH began coverage on shares of CeriBell in a research note on Friday, April 4th. They issued a "buy" rating and a $32.00 target price on the stock. Canaccord Genuity Group reissued a "buy" rating and issued a $33.00 price target on shares of CeriBell in a research note on Wednesday, February 26th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, CeriBell presently has a consensus rating of "Buy" and a consensus target price of $32.50.

Insider Buying and Selling

In other CeriBell news, CEO Xingjuan Chao sold 15,628 shares of the stock in a transaction that occurred on Wednesday, April 23rd. The stock was sold at an average price of $15.11, for a total value of $236,139.08. Following the completion of the sale, the chief executive officer now owns 727,151 shares in the company, valued at approximately $10,987,251.61. This trade represents a 2.10 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold 24,700 shares of company stock valued at $372,434 over the last ninety days.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.